Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06397846
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-03
First Post:
2024-04-30
Brief Title:
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PANORAMA
Brief Summary:
The challenge for medical oncology is to develop plasma biomarkers that can detect the influence of the stroma on diagnosis prognosis and response to chemotherapy
Today there is no validated blood test to help diagnose pancreatic cancer PDAC The search for blood biomarkers of the tumor stroma and immunological markers is therefore a major challenge in orienting the diagnosis towards PDAC and optimizing the therapeutic management of pancreatic cancers
The aim of the study is to identify biomarkers associated with the presence of malignant pancreatic lesions patients from the Pancreas-CGE cohort a cohort already set up by our team compared with benign lesions patients followed up for benign pancreatic lesions Candidate biomarkers from our preliminary work will be considered initially Other biomarkers may be explored secondarily
The ultimate goal is to develop a clinico-biological signature that is as efficient as possible in predicting the presence of malignant pancreatic lesions compared with benign ones
Today there is no validated blood test to help diagnose pancreatic cancer PDAC The search for blood biomarkers of the tumor stroma and immunological markers is therefore a major challenge in orienting the diagnosis towards PDAC and optimizing the therapeutic management of pancreatic cancers
The aim of the study is to identify biomarkers associated with the presence of malignant pancreatic lesions patients from the Pancreas-CGE cohort a cohort already set up by our team compared with benign lesions patients followed up for benign pancreatic lesions Candidate biomarkers from our preliminary work will be considered initially Other biomarkers may be explored secondarily
The ultimate goal is to develop a clinico-biological signature that is as efficient as possible in predicting the presence of malignant pancreatic lesions compared with benign ones
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None